Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Roche says rising biosimilar threat will speed up Rituxan sales fall

By John Miller 
    ZURICH, Feb 1 (Reuters) - Swiss drugmaker Roche  ROG.S  
expects erosion of Rituxan sales in Europe will intensify in 
2018 as cheaper copies made by rivals gather momentum, its drug 
unit said on Thursday. 
    Revenue for Roche's top-selling blood cancer medicine in 
Europe plunged 26 percent in the fourth quarter of 2017, after a 
16 percent third-quarter drop following patent losses.  
    Overall, the medicine's full-year sales rose by 1 percent to 
7.4 billion Swiss francs  ($7.99 billion), as sales in the 
United States -- where patents remain valid until mid-2018 -- 
offset the European slump. 
    But with more Rituxan biosimilar launches from Novartis 
 NOVN.S  and Celltrion  091990.KQ  across Europe on the way, 
O'Day said the decline will worsen.  
    "We'll see an acceleration of this exposure... all expected 
in the first half of the year," Roche pharmaceuticals chief Dan 
O'Day told analysts in London.  
    Roche on Thursday forecast U.S. tax changes would help 
profit growth outstrip sales in 2018.  urn:newsml:reuters.com:*:nL8N1PR0U4 
    But the Basel company's vulnerability to biosimilars is 
growing: Beyond Rituxan, up to five biosimilar copies of Roche's 
$7 billion-per-year cancer drug Herceptin could be introduced 
this year, O'Day said. 
    Roche Chief Executive Severin Schwan acknowledged Roche's 
2018 sales target-- for flat or low-single-digit percentage 
growth -- is "more cautious" than in years past due to 
biosimilar threat. 
 
 
($1 = 0.9267 Swiss francs) 
 
 (Reporting by John Miller, editing by John Revill) 
 ((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters 
Messaging: j.miller.thomsonreuters.com@reuters.net)) 
 
Keywords: ROCHE RESULTS/BIOSIMILARS

Recent news on Celltrion Healthcare Co

See all news